Drug Trial Radar · NCT04456673
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation
Last checked: Nov 20, 2026Latest source record: May 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
935
Actual
Start
Jul 6, 2020
Primary completion
Feb 28, 2024
Study completion May 27, 2024
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Jul 2, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate or severe Chronic Obstructive Pulmonary Disease (COPD) as measured by * Annualized rate of acute moderate or severe COPD exacerbation (AECOPD) Secondary Objectives: To evaluate the effect of dupilumab administered every 2 weeks on * Pre-bronchodilator forced expiratory volume in 1 second (FEV1) over 12 weeks compared to placebo * Health related quality of life, assessed by the change from baseline to Week 52 in the St. George's Respiratory Questionnaire (SGRQ) * Pre-bronchodilator FEV1 over 52 weeks compared to placebo * Lung function assessments * Moderate and severe COPD exacerbations * To evaluate safety and tolerability * To evaluate dupilumab systemic exposure and incidence of antidrug antibodies (ADA)
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
Dupilumab SAR231893Drug
Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
Inhaled CorticosteroidDrug
Pharmaceutical form: Inhaled Powder Route of administration: Oral inhalation
Inhaled Long-Acting Beta AgonistDrug
Pharmaceutical form: Inhaled Powder Route of administration: Oral inhalation
Inhaled Long-Acting Muscarinic AntagonistDrug
Pharmaceutical form: Inhaled Powder Route of administration: Oral inhalation
PlaceboDrug
Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-week Treatment PeriodTime frame: Baseline (Day 1) to Week 52
Locations
334 sites in 29 countries. Site status is shown where the registry gives one.
Cullman Research Center, LLC Site Number : 8400095
Cullman, Alabama
Pulmonary & Sleep Associates of Jasper PC Site Number : 8400090
Jasper, Alabama
Scottsboro Quick Care Clinic Site Number : 8400116
Scottsboro, Alabama
Phoenix Medical Group Site Number : 8400061
Peoria, Arizona
Medical Advancement Center of Arizona Site Number : 8400107
Tempe, Arizona
Asthma and Allergy Institute Site Number : 8400022
Little Rock, Arkansas
Kern Research, Inc Site Number : 8400031
Bakersfield, California
NewportNativeMD, Inc Site Number : 8400032
Newport Beach, California
Prospective Research Innovations, Inc. Site Number : 8400063
Rancho Cucamonga, California
ACRC Studies Site Number : 8400094
San Diego, California
Institute of HealthCare Assessment, Inc. Site Number : 8400015
San Diego, California
Allianz Research Institute Site Number : 8400007
Westminster, California
Innovative Clinical Research Site Number : 8400018
Lafayette, Colorado
Helix Biomedics, LLC Site Number : 8400035
Boynton Beach, Florida
Pioneer Clinical Research Site Number : 8400043
Boynton Beach, Florida
Renaissance Research and Medical Group, Inc Site Number : 8400092
Cape Coral, Florida
St. Francis Sleep, Allergy and Lung Institute Site Number : 8400020
Clearwater, Florida
Beautiful Minds Clinical Research Center Site Number : 8400081
Cutler Bay, Florida
Omega Research Consultants, LLC Site Number : 8400021
DeBary, Florida
Sciences Connections, LLC Site Number : 8400133
Doral, Florida
InvesClinic, LLC Site Number : 8400039
Fort Lauderdale, Florida
Finlay Medical Research Site Number : 8400071
Greenacres City, Florida
Direct Helpers Medical Center Inc Site Number : 8400079
Hialeah, Florida
DL Research Solutions Inc Site Number : 8400089
Miami, Florida
Phoenix Medical Research, LLC Site Number : 8400012
Miami, Florida
Columbus Clinical Services Site Number : 8400062
Miami, Florida
Reed Medical Research Site Number : 8400123
Miami, Florida
De La Cruz Research Center, LLC Site Number : 8400075
Miami, Florida
Florida Institute for Clinical Research Site Number : 8400129
Orlando, Florida
Central Florida Pulmonary Group, PA Site Number : 8400101
Orlando, Florida
Innovation Medical Research Center Site Number : 8400114
Palmetto Bay, Florida
Family Medical Specialists of Florida, PA Site Number : 8400077
Plant City, Florida
Coastal Pulmonary And Critical Care Site Number : 8400013
St. Petersburg, Florida
Florida Pulmonary Research Center Site Number : 8400001
Winter Park, Florida
Appalachian Clinical Research Site Number : 8400048
Adairsville, Georgia
Northlake Medical Group Site Number : 8400099
Atlanta, Georgia
River Birch Research, LLC Site Number : 8400045
Blue Ridge, Georgia
Medical Centre of Conyers Site Number : 8400064
Conyers, Georgia
David Kavtaradze MD, Inc. Site Number : 8400135
Cordele, Georgia
Gwinnett Biomedical Research Site Number : 8400052
Lawrenceville, Georgia
Showing 40 of 334 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.